
7 Big Questions About Cancer, Answered
The question of when and why, exactly, that happens — and what can be done to stop it — has long stumped cancer scientists and physicians. Despite the unanswered questions that remain, they have made enormous strides in understanding and treating cancer.
'We're a lot less fearful about telling patients what we do and don't know, because we know a lot more,' said Dr. George Demetri, senior vice president for experimental therapeutics at Dana-Farber Cancer Institute in Boston.
Here are some of the biggest questions about cancer that scientists have started to answer.
Why do some genetic mutations lead to cancer while others don't?
Scientists used to think that genetic mutations — changes to the letter sequence of your DNA — were the foundation of all cancers.
They were only partly right. 'Mutations are very important — but they're not the entire explanation for a tumor,' said Douglas Hanahan, a distinguished scholar at the Ludwig Institute for Cancer Research in Lausanne, Switzerland. Some mutations remain dormant our whole lives, never leading to cancer.
It's now clear that, separate from DNA mutations, there are other factors that alter how genes are expressed. These are called epigenetic changes, and scientists have discovered that they play a huge role in driving cancer.
Scientists don't fully understand what leads to epigenetic changes, but aging, dietary and environmental exposures, and chronic inflammation are all thought to be possible culprits.
Can pollution give people cancer? What about microplastics?
Scientists have long known that some chemicals, like asbestos and radon, or like those in cigarette smoke and alcohol, can cause cancer. But in recent years, some emerging research has raised alarms about the risks of air pollution and microplastics, and of per- and polyfluoroalkyl substances, or PFAS.
The science on these is still far from settled.
'There are signals that these things may be carcinogenic, but which cancers, when and how is where we have to get a lot more information,' said Dr. W. Kimryn Rathmell, the former director of the National Cancer Institute.
The evidence is strongest for air pollution. Fine particulate matter, known as PM 2.5, has been shown to increase risk for lung and breast cancers, said Dr. Loretta Erhunmwunsee, an associate professor of thoracic surgery at City of Hope, a national cancer research and treatment organization.
How much pollution you have been exposed to, and for how long, likely matters. Research shows that Black people in the United States are exposed to disproportionately high levels of air pollution; they also have higher rates of lung cancer and of death from the disease than other racial groups do.
We now understand that 'social context really does drive a lot of the cancer outcomes that we see, and actually even the development and cancer risk itself,' Dr. Erhunmwunsee said.
How is inflammation related to all this?
For years, scientists searched for chemicals in our diets and environment that caused genetic mutations. But it's becoming clear that if such exposures affect our cancer risk, they likely do so by provoking inflammation — not by directly damaging DNA, explained Robert Weinberg, a professor of biology at the Massachusetts Institute of Technology.
Take the gut: Eating an unhealthy diet can upset the balance of our microbiome, allowing certain bacteria to grow unchecked. Scientists think this may cause chronic inflammation, which can lead to colon or pancreatic cancers, said Dr. Davendra Sohal, an oncologist at the University of Cincinnati Cancer Center who specializes in gastrointestinal cancers.
Inflammation can also promote cancer in cells that have already mutated. PM 2.5 particles, for instance, have been shown to induce inflammation in the lungs, waking up dormant mutant cells to fuel tumor formation.
What gives tumors the power to grow unchecked?
Cancer is not just a group of abnormal cells growing in a way they shouldn't. Scientists now recognize that tumors are complex tissues made up of cancer cells as well as normal cells that have been recruited to support their growth.
Many of these normal cells are the same type of immune cells that will flood the site of an injury or infection to help heal that wound — by helping new cells multiply, generating blood vessels, stimulating new connective tissue and avoiding attacks from other parts of the immune system. These are capabilities that cancer cells can co-opt indefinitely to support their own growth.
'Tumors are wounds that don't heal,' Dr. Hanahan said, citing a paradigm-shifting observation first made in the 1980s by the Harvard pathologist Dr. Harold Dvorak.
Much about how tumors metastasize — spread and take up residence in faraway sites — still remains a mystery, said Dr. Kevin Cheung, an associate professor of hematology and oncology at the Fred Hutch Cancer Center in Seattle, Washington. His research recently showed that dead and dying cells within a tumor might create an environment that makes it easier for living tumor cells to get out and spread. Other research has suggested that immune cells might transfer their contents to tumor cells to make them more invasive.
What risk factors are actually in our control?
Many cancers form for reasons that are completely out of our hands. 'There will always be some cancers, even if we had the best prevention,' Dr. Rathmell said. But prevention can make a huge difference.
Epidemiologists now estimate that 40 percent of cancers, and a similar share of cancer deaths, can be attributed to risk factors that people can address. The biggest of these is cigarette smoking, but the list also includes sun exposure, alcohol use and excess body weight.
Some infections, including those caused by the hepatitis B and C viruses, human papillomavirus and H. pylori bacteria, can also cause certain cancers. Getting vaccinated for HPV and screened for hepatitis and H. pylori can reduce the risk.
What's the right way to treat it?
Just a few decades ago, cancer treatment involved a fair amount of guesswork. 'We were kind of just pushing poisons and hoping for the best,' Dr. Demetri said.
Now, though, oncologists have a clearer idea of who might benefit from chemotherapy — which delivers toxins that kill healthy cells in addition to cancer cells — and who might benefit from a more targeted treatment, like a drug that goes after a specific defective protein in a cancer.
Doctors also have better treatments, thanks in part to a more advanced understanding of the immune system's role in cancer.
'How the immune system works, what makes those cells different, what makes them active, what makes them dormant, when they get tuned up and tuned back — you had to know all that before you could try to play with the controls,' Dr. Rathmell said.
Being able to play with those controls has opened up a whole new field of cancer treatment, known as immunotherapy. Doctors can now take the brakes off T cells — the immune system fighters that kill cancer cells — with checkpoint inhibitor therapies used to treat lung and skin cancers, among many others. They can also engineer T cells to find and fight cancer. This is the approach behind CAR T-cell therapy, which has been most effective at treating blood cancers.
Is cancer ever curable?
Although people might think of a cancer as 'cured' once someone is in remission, doctors have historically been reluctant to promise they could get rid of a person's cancer completely. 'We never dared to use the word 'cure,'' said Dr. Marcel van den Brink, president of City of Hope National Medical Center. But newer treatments, like stem cell transplants and CAR T, have given him and other physicians more hope.
'It has been a sea change from, 'You will die from this cancer,' to, 'We have a litany of available, exciting therapies that we're going to work through,'' Dr. Rathmell said.
Even with no evidence of disease, some cancers can come back — and in those cases doctors are more cautious about potential outcomes.
Still, there is reason for optimism. Cancer death rates have plummeted over the last 30 years. We now have medications that target cancer-causing genes that were long considered impossible to treat.
Certain cancers used to be 'death sentences,' Dr. Sohal said. Now they are more akin to diabetes, a complicated disease that can be treated with manageable side effects: 'People live with the disease for a long time,' he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


USA Today
an hour ago
- USA Today
Kelley Mack, 'The Walking Dead' and 'Chicago Med' actress, dies at 33
Kelley Mack, a film producer and actress who appeared in "The Walking Dead" and "Chicago Med," has died. She was 33. Born Kelley Lynne Klebenow, the Chapman University graduate died Aug. 2 in her hometown of Cincinnati following a battle with glioma of the central nervous system. Her agent, Julie Smith, confirmed the news to USA TODAY on Aug. 5. According to the National Cancer Institute, gliomas are groups of tumors formed from abnormal glial cells, which "support and protect the brain's nerve cells" and are found in the brain and spinal cord. They are "the most common type of malignant primary brain tumor in adults," per the NCI. Though Mack also did work on commercials and short films, her biggest roles saw her on screen on Season 8 of "Chicago Med" as Penelope Jacobs. She also played Addy in Season 9 of "The Walking Dead." Mack's sister, Kathryn Klebenow, shared news of her death on her Instagram, writing in the caption that "It is with indelible sadness that we are announcing the passing of our dear Kelley. Such a bright, fervent light has transitioned to the beyond, where we all eventually must go." She "passed peacefully on Saturday evening with her loving mother Kristen and steadfast aunt Karen present," per the post. Klebenow added, "As her sister, I want you all to know how brave ... (she) was, especially when she decided to make the leap to be reunited with God. I'm so ... proud of her." Previously, Mack's family shared in April that she had completed proton radiation treatment. In a statement shared on Mack's CaringBridge page, Klebenow wrote that her family will be holding "a recognition and remembrance of Kelley's life" in Glendale, Ohio, on Aug. 16, with a celebration of life planned for an unspecified date in Los Angeles.


Business Journals
6 hours ago
- Business Journals
UPMC Hillman is an NCI-designated Comprehensive Cancer Center: What this means for patients
A cancer diagnosis changes someone's life—and so can the cancer center they choose for treatment. UPMC Hillman Cancer Center is western Pennsylvania's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, a distinction held by just 57 centers around the country. The NCI is our nation's leading cancer authority, and its Comprehensive Cancer Center program recognizes centers that are conducting groundbreaking research to develop new and better ways to prevent, diagnose, and treat cancer. For patients, treatment at an NCI-designated Comprehensive Cancer Center can mean better outcomes, according to a 2015 study of individuals with newly diagnosed adult-onset cancer. 'The advances that have been made of the past 10-plus years have really changed the landscape of cancer care,' says Stanley M. Marks, MD, UPMC Hillman's chairman. 'We can successfully treat difficult cancers now that 10 or 15 years ago, we never dreamt that we could. But in addition to better outcomes, the quality of life has improved.' NCI designation is earned, not paid for or determined by peer nomination. Centers must demonstrate excellence in research across multiple branches of science and among a multidisciplinary team. Every five to seven years, UPMC Hillman undergoes a rigorous evaluation—including an extensive grant application and assessments of its research activities—to maintain its status. expand From Bench to Bedside More than 300 UPMC Hillman scientists work together to investigate all aspects of cancer, from how it develops and behaves at the molecular level to how genetic, environmental, and lifestyle factors influence someone's cancer likelihood. The team engages in bench-to-bedside practices, working collaboratively with physicians to translate promising laboratory findings into new and better therapies, diagnostic tools, and prevention strategies. UPMC Hillman experts have made groundbreaking discoveries and pioneered new treatments to improve patient care, including: Discovering two of the seven known cancer-causing viruses Being the first to use natural killer cells, a type of immune cell, against cancer Demonstrating that changing the gut microbiome through fecal transplant can enable patients with melanoma who did not previously respond to immunotherapy to successfully respond Being the first to use a synthetic vaccine called MUC-1 against cancer Creating national guidelines for exercise as a means to reduce the severity of chemotherapy symptoms Developing the first vaccine targeting ductal carcinoma in situ, a type of pre-invasive breast cancer Nationally Recognized Care in Local Communities UPMC Hillman's NCI designation extends throughout its entire network, which includes nearly 80 locations in communities throughout Pennsylvania, Ohio, New York, and Maryland, well beyond its flagship facility in Pittsburgh. This means that patients can receive the latest evidence-based care and ongoing support with little or no need to travel. 'We strive for all our locations to deliver the same care the patients would receive if they came to Pittsburgh,' Dr. Marks says. 'For the most part, 90% of cancer care can be delivered in the community, and we want patients to be treated closer to home.' At UPMC Hillman Cancer Center, we understand the complexity of cancer. Learn more about our research and clinical trials here. UPMC Hillman Cancer Center is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is harnessing the expertise of physicians, scientists and allied health care professionals who deliver comprehensive clinical care, lead cutting-edge research, train future generations of cancer experts and engage with our communities to detect, treat and prevent cancer.


Business Wire
7 hours ago
- Business Wire
BioHub Maryland, Powered by the Maryland Tech Council, Partners with Bowie State University On Summer Life Sciences Training for Students
ROCKVILLE, Md.--(BUSINESS WIRE)--In a move to expand pathways into Maryland's life sciences industry, BioHub Maryland, powered by Maryland Tech Council, and Bowie State University, the state's first historically Black College/University, are partnering to give two dozen undergraduates hands-on experience in biopharmaceutical manufacturing this summer. By working with Bowie State University, we're ensuring a more robust pipeline of talent is ready to lead the next generation of biotech breakthroughs—right here in Maryland. The partnership aims to equip students with the technical skills needed to fill in-demand jobs in one of Maryland's most innovative industries. Over four weeks, students from the university's Department of Natural Sciences receive immersive, lab-based training at the BioHub Maryland Training and Education Center in Rockville— an 8,200 square-foot facility replicating real-world biopharma production environments. 'BioHub Maryland doesn't just train students—it launches careers,' said Kelly Schulz, Chief Executive Officer of the Maryland Tech Council. 'By working with Bowie State University, we're ensuring a more robust pipeline of talent is ready to lead the next generation of biotech breakthroughs—right here in Maryland.' Students will learn core biopharma manufacturing skills such as upstream processing, cell culture, and quality control—all of which are essential to the production of vaccines and other treatments. Curricula is designed by the National Institute for Bioprocessing Research and Training (NIBRT), BioHub Maryland's globally-trusted training provider. Upon completion, each student will earn a certificate recognized by life sciences employers. Training takes place at the Rockville-based BioHub Maryland Training and Education Center at Montgomery County, a state-of-the-art facility made possible by Montgomery County and the State of Maryland. The partnership between BioHub Maryland and Bowie State University accelerates Maryland's life sciences leadership. Home to 2,700 life sciences companies and 54,000 life sciences workers, the state is part of the BioHealth Capital Region, recently ranked the #3 biopharma cluster in the U.S. Bowie State's Department of Natural Sciences Chair and Professor, Dr. George Ude, and Associate Professor, Dr. Supriyo Ray, secured this opportunity for their students through a National Institute of Standards & Technology (NIST) grant. About BioHub Maryland BioHub Maryland is accelerating the life sciences industry for companies and career seekers to expand the state's global innovation advantage. A workforce initiative of the Maryland Tech Council, the largest technology and life sciences trade association in the state, BioHub Maryland enables residents of all backgrounds to compete for rewarding careers in life sciences by offering skills training, career resources, and access to job openings. BioHub Maryland also helps life sciences companies at every stage grow by showcasing their career opportunities, training the next generation of life sciences talent, and providing strategic resources for raising capital. Learn more at and follow us on LinkedIn, Instagram, Facebook, and Twitter.